Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
LDL-C fell 53% to 56% [10] compared to ezetimibe
Last reviewed: June 3, 2026 Last updated: June 3, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Enrollment grows from 0.58 million to 1.39 million
This process checks clinical results, real-world impact, and cost
Pros: Weekly injection format Supports blood sugar control Can help overweight patients gradually lose weight Usually simple to use Cons: Weight loss may be slower Common side effects include nausea and stomach discomfort Not specifically approved for weight loss Results vary more from person to person 4
In addition, the company is developing KAI-4729 (a triple agonist) and KAI-7535 (an oral GLP-1 candidate)
US$ 25.11
US$ 27.60
US$ 26.17
US$ 23.41
US$ 20.30
US$ 27.97
US$ 23.46
US$ 24.37
